12:00 AM
 | 
Aug 20, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Alemtuzumab regulatory update

Sanofi's Genzyme Corp. subsidiary withdrew cancer drug MabCampath alemtuzumab from the European market to prepare for commercialization of the anti- CD52 mAb under a different name and dosing regimen for multiple sclerosis. The U.S. version of the cancer drug, known as Campath, will also no longer be commercially available, effective Sept. 4. MabCampath/Campath was marketed for B cell...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >